HAIC Combine With Lenvatinib and Camrelizumab for Advanced HCC With PVTT
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion
chemotherapy combined with Lenvatinib and Camrelizumab compared to Lenvatinib plus
Camrelizumab for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis
(PVTT).